● neutral
Impact
PhaseApproved (accelerated approval)
Time to marketAlready approved and commercially launched in the U.S. (March 2026). Global regulatory submissions are expected to follow the ongoing Phase 2/3 COMPASS confirmatory trial.
tividenofusp alfa-eknm tividenofusp alfa Updated Oct 31
What to watch
The next near-term catalyst is Denali's Q3 2026 earnings report on November 4, 2026, where management's Q3 Avlayah revenue (guided $10-12M, up from $3.6M in Q2) will be the key commercial proof point. The longer-term binary is the confirmatory Phase 2/3 COMPASS trial readout, which will determine whether the accelerated approval converts to full approval, though no specific readout date has been announced.
Bull case
- Avlayah is the first and only FDA-approved therapy designed to cross the blood-brain barrier for Hunter syndrome, addressing the neurologic manifestations that Takeda's Elaprase cannot treat, giving it a clear differentiation and potential to become standard of care.
- The early commercial launch is exceeding expectations: Q2 2026 generated $3.6M in net product revenue (vs analyst estimates of $1.3M), and management guided Q3 2026 to $10-12M, implying rapid quarter-over-quarter growth.
- Denali has a strong balance sheet with pro forma cash exceeding $1.1B after the $195M PRV sale, providing runway to fund its broader pipeline including DNL126 (Sanfilippo syndrome) and Alzheimer's programs through multiple catalysts.
Bear case
- Avlayah's accelerated approval was based on a biomarker surrogate (CSF heparan sulfate) in a 47-patient open-label Phase 1/2 trial; full approval depends on the ongoing Phase 2/3 COMPASS confirmatory trial, which could fail to show clinical benefit and jeopardize the label.
- The drug carries a list price of roughly $270,000 to over $811,000 per year depending on patient weight, which could face payer access and reimbursement headwinds in a rare disease market currently served by Takeda's Elaprase.
- Insider selling was detected in the evidence window (CMO, directors, COFO sold shares in Aug-Sep 2026), and several institutional holders trimmed or exited positions in Q2 2026, including a near-exit by Alyeska Investment Group.